| Full text | |
| Author(s): |
Joaquim, Helena P. G.
[1, 2]
;
Costa, Alana Caroline
[1, 2]
;
Serpa, Mauricio Henriques
[3]
;
Talib, Leda L.
[1, 2]
;
Gattaz, Wagner F.
[1, 2]
Total Authors: 5
|
| Affiliation: | [1] Conselho Nacl Desenvolvimento Cient & Tecnol, Inst Nacl Biomarcadores Neuropsiquiatria INBION, Sao Paulo - Brazil
[2] Univ Sao Paulo, Lab Neurosci LIM 27, Dept & Inst Psychiat, Rua Dr Ovidio Pires de Campos 785, 3 Andar, BR-05403010 Sao Paulo, SP - Brazil
[3] Univ Sao Paulo, Dept & Inst Psychiat, Lab Psychiat Neuroimaging LIM 21, Med Sch, Sao Paulo - Brazil
Total Affiliations: 3
|
| Document type: | Journal article |
| Source: | EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE; v. 270, n. 4, p. 489-494, JUN 2020. |
| Web of Science Citations: | 0 |
| Abstract | |
The cellular and molecular mechanisms underlying onset and development of schizophrenia have not yet been completely elucidated, but the association of disturbed neuroplasticity and inflammation has gained particular relevance recently. These mechanisms are linked to annexins functions. ANXA3, particularly, is associated to inflammation and membrane metabolism cascades. The aim was to determine the ANXA3 levels in first-onset drug-naive psychotic patients. We investigated by western blot the protein expression of annexin A3 in platelets of first-onset, drug-naive psychotic patients (diagnoses according to DSM-IV: 28 schizophrenia, 27 bipolar disorder) as compared to 30 age- and gender-matched healthy controls. Annexin A3 level was lower in schizophrenia patients as compared to healthy controls (p < 0.001) and to bipolar patients (p < 0.001). Twenty out of 28 schizophrenic patients had undetectable annexin A3 levels, as compared to none from the bipolar and none from the control subjects. ANXA3 was reduced in drug-naive patients with schizophrenia. ANXA3 affects neuroplasticity, inflammation and apoptosis, as well as it modulates membrane phospholipid metabolism. All these processes have been discussed in regard to the biology of schizophrenia. In face of these data, we feel that further studies with larger samples are warranted to investigate the possible role of reduced ANXA3 as a possible risk marker for schizophrenia. (AU) | |
| FAPESP's process: | 14/50873-3 - INCT 2014: National Institute of Biomarkers in Neuropsychiatry |
| Grantee: | Wagner Farid Gattaz |
| Support Opportunities: | Research Projects - Thematic Grants |
| FAPESP's process: | 14/20913-3 - Determination of plasma phospholipids in neuropsychiatric disorders |
| Grantee: | Alana Caroline Costa |
| Support Opportunities: | Scholarships in Brazil - Master |